Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (16)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shorr, A. F.
Right arrow Articles by O’Grady, N. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shorr, A. F.
Right arrow Articles by O’Grady, N. P.
(Chest. 2004;125:260-271.)
© 2004 American College of Chest Physicians

Pulmonary Infiltrates in the Non-HIV-Infected Immunocompromised Patient*

Etiologies, Diagnostic Strategies, and Outcomes

Andrew F. Shorr, MD, MPH; Gregory M. Susla, PharmD and Naomi P. O’Grady, MD

* From the Pulmonary and Critical Care Medicine Service, Walter Reed Army Medical Center, Washington, DC; and the Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD.

Correspondence to: Andrew F. Shorr, MD, MPH, Pulmonary and Critical Care Medicine Service, Walter Reed Army Medical Center, 6900 Georgia Ave NW, Washington, DC 20307; e-mail: afshorr{at}dnamail.com

Pulmonary complications remain a major cause of both morbidity and mortality in immunocompromised patients. When such individuals present with radiographic infiltrates, the clinician faces a diagnostic challenge. The differential diagnosis in this setting is broad and includes both infectious and noninfectious processes. Rarely are the radiographic findings classic for one disease, and most potential etiologies have overlapping clinical and radiographic appearances. In recent years, several themes have emerged in the literature on this topic. First, an aggressive approach to identifying a specific etiology is necessary; as a corollary, diagnostic delay increases the risk for mortality. Second, the evaluation of these infiltrates nearly always entails bronchoscopy. Bronchoscopy allows identification of some etiologies with certainty, and often allows for the exclusion of infectious agents even if the procedure is otherwise unrevealing. Third, early use of CT scanning regularly demonstrates lesions missed by plain radiography. Despite these advances, initial therapeutic interventions include the use of broad-spectrum antibiotics and other anti-infectives in order to ensure that the patients is receiving appropriate therapy. With the results of invasive testing, these treatments are then narrowed. Frustratingly, outcomes for immunocompromised patients with infiltrates remain poor.

Key Words: bronchoscopy • complications • fungus • immunocompromised • infection • infiltrates • malignancy • outcomes • transplant




This article has been cited by other articles:


Home page
ChestHome page
D. Stolz, A. Stulz, B. Muller, A. Gratwohl, and M. Tamm
BAL Neutrophils, Serum Procalcitonin, and C-Reactive Protein To Predict Bacterial Infection in the Immunocompromised Host
Chest, August 1, 2007; 132(2): 504 - 514.
[Abstract] [Full Text] [PDF]

eLetters:

Read all eLetters

Untitled
Denis Caillot
Chest Online, 14 Jan 2004 [Full text]



HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American College of Chest Physicians.